[Mean platelet volume: interactions with platelet aggregation activity and glycoprotein IIb-IIIa and Ib expression levels]
- PMID: 24749250
- DOI: 10.18097/pbmc20146001094
[Mean platelet volume: interactions with platelet aggregation activity and glycoprotein IIb-IIIa and Ib expression levels]
Abstract
Increased mean platelet volume (MPV) is an independent risk factor of thrombotic events in patients with cardiovascular diseases. Interactions of MPV with platelet aggregation activity and contents of glycoprotein (GP) IIb-IIIa (alphaIIb/beta3 integrin, fibrinogen receptor) and GP Ib (von Willebrand factor receptor) were investigated in this study. Investigation was performed in a group of healthy volunteers (n = 38) and in a group of patients with acute coronary syndrome (ACS). In patients blood was collected at days 1, 3-5 and 8-12 after ACS development. As an antiaggregant therapy all patients received acetylsalicylic acid (ASA, inhibitor of thromboxane A2 synthesis) and most of them--clopidogrel (ADP receptor antagonist) with the exception of part of the patients (n = 44) at day 1 who had not taken clopidogrel before first blood collection. In volunteers platelet aggregation was stimulated by 1.25, 2.5, 5 and 20 M ADP, and in patients--by 5 and 20 M ADP. GP IIb-IIIa and GP Ib content on platelet surface was measured using 125I-labelled monoclonal antibodies. GP IIb-IIIa and GP Ib genetic polymorphisms were determined in ACS patients. In healthy donors significant correlations between MPV and aggregation levels were revealed at 1.25 and 2.5 M ADP (coefficients of correlation (r)--0.396 and 0.373, p < 0.05) and at 5 and 20 those interactions did not reach significant level (r--0.279 and 0.205, p > 0.05). Correlations between MPV and aggregation levels were observed at day 1 of ACS in a subgroup of patients who received ASA but had not started clopidogrel treatment (r--0.526, p < 0.01 and 0.368, p < 0.05 for 5 and 20 M ADP respectively). Interactions between these parameters were not registered upon combined treatment with ASA and clopidogrel. Strong direct correlations between MPV and GP IIb-IIIa and GP Ib contents were detected in healthy donors and ACS patients (at all time points) -r from 0.439 to 0.647 (p < or = 0.001 for all correlations). Genetic polymorphisms of GP IIb-IIIa (GP IIIa Leu33Pro) and GP Ib ((-5)T/C (Kozak) and Thr145Met) identified in ACS patients did not affect expression levels of corresponding glycoproteins. The data obtained indicated that increased MPV values correlate with increased platelet aggregation activity and enhanced GP IIb-IIIa and GP Ib expression.
Similar articles
-
[Platelet aggregation upon acetylsalicylic acid and clopidogrel treatment and glycoprotein IIb/IIIa content in patients with acute coronary syndrome].Kardiologiia. 2011;51(7):4-7. Kardiologiia. 2011. PMID: 21878077 Russian.
-
Glycoprotein IIb-IIIa content and platelet aggregation in healthy volunteers and patients with acute coronary syndrome.Platelets. 2011;22(4):243-51. doi: 10.3109/09537104.2010.547959. Epub 2011 Feb 17. Platelets. 2011. PMID: 21329420 Review.
-
[Factors influencing platelet aggregation in patients with acute coronary syndrome].Ter Arkh. 2014;86(9):83-9. Ter Arkh. 2014. PMID: 25518511 Russian.
-
Relationships of glycoproteins IIb-IIIa and Ib content with mean platelet volume and their genetic polymorphisms.Blood Coagul Fibrinolysis. 2014 Mar;25(2):128-34. doi: 10.1097/MBC.0b013e328364b025. Blood Coagul Fibrinolysis. 2014. PMID: 23941967
-
Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?Vasc Health Risk Manag. 2006;2(1):39-48. doi: 10.2147/vhrm.2006.2.1.39. Vasc Health Risk Manag. 2006. PMID: 17319468 Free PMC article. Review.
Cited by
-
Receptor GP IIb/IIIa as an Indicator of Risk in Vascular Events.Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619845056. doi: 10.1177/1076029619845056. Clin Appl Thromb Hemost. 2019. PMID: 31185733 Free PMC article.
-
Nonalcoholic Fatty Liver Disease-Evidence for a Thrombophilic State?Curr Pharm Des. 2020;26(10):1036-1044. doi: 10.2174/1381612826666200131101553. Curr Pharm Des. 2020. PMID: 32003679 Free PMC article. Review.
-
Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy.J Thromb Thrombolysis. 2016 Aug;42(2):245-53. doi: 10.1007/s11239-016-1348-1. J Thromb Thrombolysis. 2016. PMID: 26951167
-
Early administration of tirofiban after urokinase-mediated intravenous thrombolysis reduces early neurological deterioration in patients with branch atheromatous disease.J Int Med Res. 2020 May;48(5):300060520926298. doi: 10.1177/0300060520926298. J Int Med Res. 2020. PMID: 32459110 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials